>Mercado Europeu de Terapêutica de Transplantação Pulmonar, por Produto (Medicamentos Imunossupressores, Produtos de Preservação de Órgãos, Produtos de Tecidos e Outros), Indicação ( Doenças Pulmonares Obstrutivas Crónicas (DPOC), Fibrose Pulmonar, Doença Pulmonar Séptica, Hipertensão Pulmonar, Fibrose Quística, Fibrose Pulmonar Intersticial , Enfisema, Sarcoidose, Hipertensão Arterial Pulmonar Primária e Outros), Tipo (Transplante Pulmonar Cadavérico, Transplante Pulmonar Vivo), Técnica (Transplante Pulmonar Unilateral, Transplante Pulmonar Bilateral, Transplante Coração-Pulmão e Transplante Pulmonar Duplo), Demografia do Doente ( Geriátrico, Adulto, Pediátrico), Utentes Finais (Hospital, Centros de Transplantação, Centros Especializados e Outros), País (Alemanha, Espanha, França, Itália, Reino Unido, Bélgica, Países Baixos, Suíça, Rússia, Turquia, Resto da Europa) Tendências da Indústria e Previsão para 2029
Análise de Mercado e Insights : Mercado Europeu de Terapêutica de Transplantação Pulmonar
Espera-se que o mercado europeu de terapêutica para transplante pulmonar ganhe crescimento de mercado no período de previsão de 2022 a 2029. A Data Bridge Market Research analisa que o mercado está a crescer com um CAGR de 4,0% no período de previsão de 2022 a 2029 e deverá atingir os 64,15 milhões de dólares até 2029. Espera-se que o lançamento de novos produtos pelos principais players do mercado impulsione a procura do mercado no período de previsão.
Um transplante pulmonar é uma cirurgia realizada para remover um pulmão doente e substituí-lo por um pulmão saudável de outra pessoa. A cirurgia de transplante pulmonar pode ser realizada em pessoas de quase todas as idades, desde recém-nascidos a adultos até aos 65 anos e, por vezes, até mais tarde. Um transplante pulmonar é para pessoas que tentaram outros medicamentos ou tratamentos, mas as suas condições subjacentes não melhoraram suficientemente ou pioraram ao longo do tempo. Dependendo da condição médica do paciente, um transplante pulmonar pode envolver a substituição de um pulmão ou de ambos. Os pulmões podem ser transplantados com o coração de um dador em algumas situações. Um transplante pulmonar pode melhorar significativamente a saúde e a qualidade de vida do doente.
Espera-se que o aumento das aprovações de medicamentos, o aumento dos ensaios clínicos, a elevada incidência de doenças crónicas e algumas pesquisas em curso para aumentar a aplicação terapêutica impulsionem o crescimento do mercado. No entanto, menos dadores para doação de órgãos e o elevado custo dos procedimentos de transplante pulmonar podem dificultar o crescimento do mercado. Entretanto, o aumento dos gastos em saúde, as iniciativas estratégicas dos participantes do mercado e os avanços tecnológicos no transplante pulmonar podem criar oportunidades para o crescimento do mercado. O quadro regulamentar rigoroso e as complicações associadas ao transplante pulmonar podem desafiar o crescimento do mercado.
O relatório do mercado terapêutico de transplante pulmonar da Europa fornece detalhes da quota de mercado, novos desenvolvimentos e análise do pipeline de produtos, o impacto dos participantes do mercado doméstico e localizado, analisa as oportunidades em termos de bolsas de receitas emergentes, alterações nas regulamentações de mercado, aprovações de produtos, decisões estratégicas, lançamentos de produtos, expansões geográficas e inovações tecnológicas no mercado. Para compreender a análise e o cenário do mercado, contacte-nos para um resumo do analista; a nossa equipa irá ajudá-lo a criar uma solução de impacto na receita para atingir a meta desejada.
Âmbito do mercado de terapêutica de transplante pulmonar da Europa e dimensão do mercado
O mercado europeu de terapêutica para transplante pulmonar está segmentado em produto, tipo, indicação, técnica, demografia do paciente e utilizadores finais. O crescimento entre segmentos ajuda-o a analisar os nichos de crescimento e as estratégias para abordar o mercado e determinar as suas principais áreas de aplicação e a diferença nos seus mercados-alvo.
- Com base no produto, o mercado europeu de terapêutica para transplante pulmonar está segmentado em medicamentos imunossupressores, produtos de tecidos, produtos de preservação de órgãos, entre outros. Em 2022, prevê-se que o segmento dos medicamentos imunossupressores domine o mercado europeu de terapêutica para o transplante pulmonar devido ao aumento do consumo de medicamentos supressores do sistema imunitário em combinação com outros medicamentos pelos doentes para evitar a rejeição pulmonar ampla disponibilidade destes medicamentos em hospitais e lojas de retalho .
- Com base no tipo, o mercado europeu de terapêutica para transplante pulmonar está segmentado em transplante pulmonar cadavérico e transplante pulmonar vivo. Em 2022, prevê-se que o segmento do transplante pulmonar cadavérico domine o mercado europeu de terapêutica para o transplante pulmonar devido ao aumento da sensibilização das organizações não governamentais e de várias outras joint ventures internas em relação à doação de órgãos e às suas aplicações.
- Com base na indicação, o mercado europeu de terapêutica para transplante pulmonar está segmentado em doenças pulmonares obstrutivas crónicas (DPOC), fibrose pulmonar, doença pulmonar séptica, hipertensão pulmonar, fibrose quística, fibrose pulmonar intersticial, enfisema, hipertensão arterial pulmonar primária, sarcoidose , entre outros. Em 2022, prevê-se que o segmento da fibrose quística domine o mercado global de terapêutica para o transplante pulmonar devido ao aumento da população de doentes com fibrose quística na região.
- Com base na técnica, o mercado europeu de terapêutica para transplante pulmonar está segmentado em transplante de pulmão único, transplante pulmonar bilateral, transplante coração-pulmão e transplante duplo de pulmão. Em 2022, prevê-se que o segmento de transplante de pulmão único (SLT) domine o mercado europeu de terapêutica para transplante pulmonar devido ao aumento dos procedimentos de transplante pulmonar na Bélgica, Espanha e Alemanha com outras regiões.
- Com base na demografia dos doentes, o mercado europeu de terapêutica para transplante pulmonar está segmentado em adulto, pediátrico e geriátrico. Em 2022, prevê-se que o segmento adulto domine o mercado europeu de terapêutica para transplante pulmonar devido ao aumento das complicações de saúde observadas na população adulta e ao aumento da lista de espera de doentes adultos à espera de transplante, o que determinaria o procedimento de transplante pulmonar.
- Com base nos utilizadores finais, o mercado europeu de terapêutica para transplante pulmonar está segmentado em hospitais, centros de transplantação, centros especializados, entre outros. Em 2022, prevê-se que o segmento hospitalar domine o mercado europeu de terapêutica para transplante pulmonar devido aos hospitais como o principal ponto de saúde e local eficaz para cirurgias com médicos qualificados e maior sensibilização para a doação de órgãos, registo e doenças crónicas.
Mercado Europeu de Terapêutica de Transplantação Pulmonar Análise a nível de país
O mercado europeu de terapêutica para transplante pulmonar é analisado e são fornecidas informações sobre o tamanho do mercado com base no produto, tipo, indicação, técnica, demografia do paciente e utilizadores finais.
Alguns dos países abrangidos pelo mercado europeu de terapêutica para transplante pulmonar são a Alemanha, Espanha, França, Itália, Reino Unido, Bélgica, Países Baixos, Suíça, Rússia, Turquia e o resto da Europa.
Prevê-se que o segmento dos medicamentos imunossupressores na região da Europa cresça com a maior taxa de crescimento no período previsto de 2022 a 2029 devido ao aumento dos ensaios clínicos e ao desenvolvimento de investigação para prevenir doenças crónicas. Espera-se que a Alemanha lidere o crescimento do mercado europeu devido ao aumento das cirurgias de transplante pulmonar a cada ano, resultando numa maior aprovação de medicamentos para transplante. Espera-se que Espanha domine com um aumento contínuo dos investimentos em investigação e desenvolvimento, o que alimenta a inovação farmacêutica.
A secção do país do relatório também fornece fatores individuais de impacto no mercado e alterações na regulamentação do mercado que impactam as tendências atuais e futuras do mercado. Dados como novas vendas, vendas de reposição, demografia do país, atos regulamentares e tarifas de importação e exportação são alguns dos principais indicadores utilizados para prever o cenário de mercado para países individuais. Além disso, a presença e disponibilidade das marcas europeias e os desafios enfrentados devido à grande ou escassa concorrência das marcas locais e nacionais, o impacto dos canais de vendas são considerados ao mesmo tempo que fornecem uma análise de previsão dos dados do país.
Iniciativas Estratégicas Apreciativas por parte dos Participantes do Mercado
O mercado europeu de terapêutica para transplante pulmonar também fornece análises de mercado detalhadas para o crescimento de cada país na indústria de transplante pulmonar com vendas, o impacto do avanço na tecnologia de transplante pulmonar e mudanças nos cenários regulamentares com o seu apoio ao mercado de terapêutica para transplante pulmonar. Os dados estão disponíveis para o período histórico de 2011 a 2020.
Cenário competitivo e análise da quota de mercado da terapêutica de transplante pulmonar na Europa
O panorama competitivo do mercado europeu de terapêutica para transplante pulmonar fornece detalhes do concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, localizações e instalações de produção, pontos fortes e fracos da empresa, lançamento de produtos, pipelines de testes de produtos, aprovações de produtos, patentes, largura do produto, e amplitude, domínio de aplicação, curva de segurança tecnológica. Os dados acima referidos estão apenas relacionados com o foco da empresa no mercado europeu de terapêutica para transplante pulmonar.
Alguns dos principais fabricantes do mercado europeu de terapêutica para transplante pulmonar são a Apotex Inc, Intas Pharmaceuticals Ltd., Viatris Inc., BioLife Solutions, Paragonix Technologies, Inc, Ose-immuno, XVIVO, Pfizer Inc., F.Hoffmann-La Roche Ltd., Panacea Biotec Ltd., Astellas Pharma Inc., Accord-UK Ltd, Novartis AG, Hikma Pharmaceuticals PLC, Dr. Franz Köhler Chemie GmbH, Detraxi Inc, Dr.
Vários participantes no mercado prestam melhores serviços de saúde, acelerando também o mercado europeu de terapêutica para o transplante pulmonar.
Por exemplo,
- Em janeiro de 2022, a Hikma Pharmaceuticals PLC expandiu-se no Canadá com ativos injetáveis estéreis Teligent, incluindo um portefólio de 25 produtos injetáveis estéreis, três produtos oftalmológicos licenciados e um pipeline de sete produtos adicionais, quatro dos quais são aprovados pela Health Canada. Este interessante portfólio de produtos permitirá à empresa expandir o negócio na América do Norte e desenvolver uma posição sólida neste importante mercado
Colaboração, lançamento de produtos, expansão de negócios, prémios e reconhecimento, joint ventures e outros participantes do mercado melhoram a empresa no mercado europeu de terapêutica para transplante pulmonar, o que também beneficia a organização para melhorar a sua oferta.
SKU-
Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo
- Painel interativo de análise de dados
- Painel de análise da empresa para oportunidades de elevado potencial de crescimento
- Acesso de analista de pesquisa para personalização e customização. consultas
- Análise da concorrência com painel interativo
- Últimas notícias, atualizações e atualizações Análise de tendências
- Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Índice
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET END USERS COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 EPIDEMIOLOGY
4.2 PESTEL ANALYSIS
4.3 PORTER’S FIVE FORCES MODEL
5 INSURANCE AND REIMBURSEMENT - EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET
5.1 U.S.
5.2 EUROPE
5.3 CANADA
5.4 INDIA
6 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: REGULATIONS
6.1 REGULATION IN THE U.S.
6.2 REGULATION IN EUROPE
6.3 REGULATION IN NEW ZEALAND
6.4 REGULATION IN AUSTRALIA
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASE IN INCIDENCE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
7.1.2 RISE IN AIR POLLUTION AND SURGE IN SMOKING
7.1.3 HIGH INCIDENCE OF CHRONIC DISEASES
7.1.4 RISE IN CLINICAL TRIALS
7.1.5 INCREASING DRUG APPROVALS
7.2 RESTRAINTS
7.2.1 LESS NUMBER OF DONORS FOR ORGAN DONATION
7.2.2 HIGH COST OF ORGAN TRANSPLANTATION
7.3 OPPORTUNITIES
7.3.1 RISING HEALTHCARE SPENDING
7.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS
7.3.3 TECHNOLOGICAL ADVANCEMENTS IN LUNG TRANSPLANTATION
7.4 CHALLENGES
7.4.1 STRINGENT REGULATORY FRAMEWORK
7.4.2 COMPLICATIONS ASSOCIATED WITH LUNG TRANSPLANTATION
8 IMPACT OF COVID-19 ON LUNG TRANSPLANT THERAPEUTICS MARKET
8.1 IMPACT ON PRICE
8.2 IMPACT ON DEMAND
8.3 IMPACT ON SUPPLY CHAIN
8.4 STRATEGIC INITIATIVES
8.5 CONCLUSION
9 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT
9.1 OVERVIEW
9.2 IMMUNOSUPPRESSANT DRUGS
9.2.1 BY CLASS
9.2.1.1 CALCINEURIN INHIBITORS
9.2.1.1.1 TACROLIMUS
9.2.1.1.2 CYCLOSPORIN
9.2.1.2 ANTIMETABOLITE IMMUNOSUPPRESANTS
9.2.1.2.1 MYCOPHENOLATE MOFETIL
9.2.1.2.2 MYCOPHENOLATE SODIUM
9.2.1.2.3 AZATHIOPRINE
9.2.1.3 M-TOR INHIBITOR
9.2.1.3.1 SIROLIMUS
9.2.1.3.2 EVEROLIMUS
9.2.1.4 STEROIDS
9.2.1.4.1 METHYLPREDNISOLONE
9.2.1.4.2 PREDNISONE
9.2.1.5 MONOCLONAL ANTIBODY
9.2.1.5.1 BASILIXIMAB
9.2.1.5.2 MUROMONAB
9.2.1.6 OTHERS
9.2.2 BY DRUG TYPE
9.2.2.1 BRANDED
9.2.2.2 GENERIC
9.2.3 ROUTE OF ADMINISTRATION
9.2.3.1 ORAL ADMINISTRATION
9.2.3.2 PARENTERAL ADMINISTRATION
9.3 ORGAN PRESERVATION PRODUCTS
9.3.1 PERFADEX
9.3.2 HUMAN BIOSYSTEM (HBS) SOLUTION
9.3.3 LIFOR
9.3.4 CUSTODIOL HTK-(HISTIDINE-TRYPTOPHAN-KETOGLUTARATE) SOLUTION
9.3.5 RENOGRAF
9.3.6 OTHERS
9.4 TISSUE PRODUCT
9.5 OTHERS
10 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE
10.1 OVERVIEW
10.2 SINGLE-LUNG TRANSPLANT (SLT)
10.3 DOUBLE LUNG TRANSPLANT
10.4 BILATERAL LUNG TRANSPLANT (BLT)
10.5 HEART-LUNG TRANSPLANT
11 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS
11.1 OVERVIEW
11.2 ADULTS
11.3 GERIATRIC
11.4 PEDIATRIC
12 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE
12.1 OVERVIEW
12.2 CADAVERIC LUNG TRANSPLANT
12.3 LIVING LUNG TRANSPLANT
13 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION
13.1 OVERVIEW
13.2 CYSTIC FIBROSIS
13.3 PULMONARY FIBROSIS
13.4 CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
13.5 INTERSTITIAL PULMONARY FIBROSIS
13.6 PULMONARY HYPERTENSION
13.7 PRIMARY PULMONARY ARTERIAL HYPERTENSION
13.8 EMPHYSEMA
13.9 SARCOIDOSIS
13.1 SEPTIC LUNG DISEASE
13.11 OTHERS
14 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITAL
14.3 TRANSPLANT CENTERS
14.4 SPECIALTY CENTERS
14.5 OTHERS
15 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION
15.1 EUROPE
15.1.1 GERMANY
15.1.2 SPAIN
15.1.3 FRANCE
15.1.4 ITALY
15.1.5 U.K.
15.1.6 BELGIUM
15.1.7 NETHERLANDS
15.1.8 SWITZERLAND
15.1.9 RUSSIA
15.1.10 TURKEY
15.1.11 REST OF EUROPE
16 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: EUROPE
17 SWOT ANALYSIS
18 COMPANY PROFILE
18.1 ASTELLAS PHARMA INC.
18.1.1 COMPANY SNAPSHOT
18.1.2 REVENUE ANALYSIS
18.1.3 COMPANY SHARE ANALYSIS
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENT
18.2 TRANSMEDICS (A SUBSIDIARY OF TRANSMEDICS GROUP, INC)
18.2.1 COMPANY SNAPSHOT
18.2.2 REVENUE ANALYSIS
18.2.3 COMPANY SHARE ANALYSIS
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENT
18.3 DR. REDDY’S LABORATORIES LTD.
18.3.1 COMPANY SNAPSHOT
18.3.2 REVENUE ANALYSIS
18.3.3 COMPANY SHARE ANALYSIS
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPMENT
18.4 F.HOFFMANN-LA ROCHE LTD.
18.4.1 COMPANY SNAPSHOT
18.4.2 REVENUE ANALYSIS
18.4.3 COMPANY SHARE ANALYSIS
18.4.4 PRODUCT PORTFOLIO
18.4.5 RECENT DEVELOPMENT
18.5 HIKMA PHARMACEUTICALS PLC
18.5.1 COMPANY SNAPSHOT
18.5.2 REVENUE ANALYSIS
18.5.3 COMPANY SHARE ANALYSIS
18.5.4 PRODUCT PORTFOLIO
18.5.5 RECENT DEVELOPMENT
18.6 APOTEX INC
18.6.1 COMPANY SNAPSHOT
18.6.2 PRODUCT PORTFOLIO
18.6.3 RECENT DEVELOPMENT
18.7 XVIVO
18.7.1 COMPANY SNAPSHOT
18.7.2 REVENUE ANALYSIS
18.7.3 PRODUCT PORTFOLIO
18.7.4 RECENT DEVELOPMENT
18.8 ACCORD-UK LTD
18.8.1 COMPANY SNAPSHOT
18.8.2 PRODUCT PORTFOLIO
18.8.3 RECENT DEVELOPMENT
18.9 BIOLIFE SOLUTIONS
18.9.1 COMPANY SNAPSHOT
18.9.2 REVENUE ANALYSIS
18.9.3 PRODUCT PORTFOLIO
18.9.4 RECENT DEVELOPMENT
18.1 BRIDGE TO LIFE LTD
18.10.1 COMPANY SNAPSHOT
18.10.2 PRODUCT PORTFOLIO
18.10.3 RECENT DEVELOPMENT
18.11 DETRAXI, INC.
18.11.1 COMPANY SNAPSHOT
18.11.2 PRODUCT PORTFOLIO
18.11.3 RECENT DEVELOPMENT
18.12 DR.FRANZ KOHLER CHEMIE GBMH
18.12.1 COMPANY SNAPSHOT
18.12.2 PRODUCT PORTFOLIO
18.12.3 RECENT DEVELOPMENT
18.13 INTAS PHARMACEUTICALS LTD.
18.13.1 COMPANY SNAPSHOT
18.13.2 PRODUCT PORTFOLIO
18.13.3 RECENT DEVELOPMENT
18.14 NOVARTIS AG
18.14.1 COMPANY SNAPSHOT
18.14.2 REVENUE ANALYSIS
18.14.3 PRODUCT PORTFOLIO
18.14.4 RECENT DEVELOPMENT
18.15 OSE-IMMUNO
18.15.1 COMPANY SNAPSHOT
18.15.2 PRODUCT PORTFOLIO
18.15.3 RECENT DEVELOPMENT
18.16 PANACEA BIOTEC LTD.
18.16.1 COMPANY SNAPSHOT
18.16.2 REVENUE ANALYSIS
18.16.3 PRODUCT PORTFOLIO
18.16.4 RECENT DEVELOPMENT
18.17 PARAGONIX TECHNOLOGIES, INC
18.17.1 COMPANY SNAPSHOT
18.17.2 PRODUCT PORTFOLIO
18.17.3 RECENT DEVELOPMENTS
18.17.3.1 PRODUCT LAUNCH
18.17.3.2 PARTNERSHIP
18.18 PFIZER INC.
18.18.1 COMPANY SNAPSHOT
18.18.2 REVENUE ANALYSIS
18.18.3 PRODUCT PORTFOLIO
18.18.4 RECENT DEVELOPMENT
18.19 VIATRIS, INC
18.19.1 COMPANY SNAPSHOT
18.19.2 REVENUE ANALYSIS
18.19.3 PRODUCT PORTFOLIO
18.19.4 RECENT DEVELOPMENT
18.20ST CENTURY MEDICINE
18.20.1 COMPANY SNAPSHOT
18.20.2 PRODUCT PORTFOLIO
18.20.3 RECENT DEVELOPMENT
19 QUESTIONNAIRE
20 RELATED REPORTS
Lista de Tabela
TABLE 1 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 2 EUROPE IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 3 EUROPE IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 4 EUROPE CALCINEURIN INHIBITORS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 5 EUROPE ANTIMETABOLITE IMMUNOSUPPRESANTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 6 EUROPE M-TOR INHIBITOR IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 7 EUROPE STEROIDS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 8 EUROPE MONOCLONAL ANTIBODY IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 9 EUROPE IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 10 EUROPE IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 11 EUROPE ORGAN PRESERVATION PRODUCTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 EUROPE ORGAN PRESERVATION PRODUCTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 13 EUROPE TISSUE PRODUCT IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 EUROPE OTHERS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 16 EUROPE SINGLE-LUNG TRANSPLANT (SLT) IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 EUROPE DOUBLE LUNG TRANSPLANT IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 EUROPE BILATERAL LUNG TRANSPLANT (BLT) IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 EUROPE HEART-LUNG TRANSPLANT IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)
TABLE 21 EUROPE ADULTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 EUROPE GERIATRIC IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 23 EUROPE PEDIATRIC IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 25 EUROPE CADAVERIC LUNG TRANSPLANT IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 EUROPE LIVING LUNG TRANSPLANT IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 28 EUROPE CYSTIC FIBROSIS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 29 EUROPE PULMONARY FIBROSIS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 EUROPE INTERSTITIAL PULMONARY FIBROSIS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 EUROPE PULMONARY HYPERTENSION IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 EUROPE PRIMARY PULMONARY ARTERIAL HYPERTENSION IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 34 EUROPE EMPHYSEMA IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 35 EUROPE SARCOIDOSIS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 36 EUROPE SEPTIC LUNG DISEASE IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 37 EUROPE OTHERS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 38 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 39 EUROPE HOSPITAL IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 40 EUROPE TRANSPLANT CENTERS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 41 EUROPE SPECIALTY CENTERS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 42 EUROPE OTHERS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 43 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 44 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 45 EUROPE IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 46 EUROPE CALCINEURIN INHIBITORS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 47 EUROPE ANTIMETABOLITE IMMUNOSUPPRESANTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 48 EUROPE M-TOR INHIBITOR IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 49 EUROPE STEROIDS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 50 EUROPE MONOCLONAL ANTIBODY IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 51 EUROPE IMMUNOSUPRRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 52 EUROPE IMMUNOSUPPRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 53 EUROPE ORGAN PRESERVATION PRODUCTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 54 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 55 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 56 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 57 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)
TABLE 58 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 59 GERMANY LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 60 GERMANY IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 61 GERMANY CALCINEURIN INHIBITORS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 62 GERMANY ANTIMETABOLITE IMMUNOSUPPRESANTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 63 GERMANY M-TOR INHIBITOR IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 64 GERMANY STEROIDS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 65 GERMANY MONOCLONAL ANTIBODY IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 66 GERMANY IMMUNOSUPRRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 67 GERMANY IMMUNOSUPPRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 68 GERMANY ORGAN PRESERVATION PRODUCTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 69 GERMANY LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 70 GERMANY LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 71 GERMANY LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 72 GERMANY LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)
TABLE 73 GERMANY LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 74 SPAIN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 75 SPAIN IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 76 SPAIN CALCINEURIN INHIBITORS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 77 SPAIN ANTIMETABOLITE IMMUNOSUPPRESANTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 78 SPAIN M-TOR INHIBITOR IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 79 SPAIN STEROIDS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 80 SPAIN MONOCLONAL ANTIBODY IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 81 SPAIN IMMUNOSUPRRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 82 SPAIN IMMUNOSUPPRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 83 SPAIN ORGAN PRESERVATION PRODUCTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 84 SPAIN LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 85 SPAIN LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 86 SPAIN LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 87 SPAIN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)
TABLE 88 SPAIN LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 89 FRANCE LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 90 FRANCE IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 91 FRANCE CALCINEURIN INHIBITORS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 92 FRANCE ANTIMETABOLITE IMMUNOSUPPRESANTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 93 FRANCE M-TOR INHIBITOR IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 94 FRANCE STEROIDS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 95 FRANCE MONOCLONAL ANTIBODY IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 96 FRANCE IMMUNOSUPRRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 97 FRANCE IMMUNOSUPPRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 98 FRANCE ORGAN PRESERVATION PRODUCTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 99 FRANCE LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 100 FRANCE LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 101 FRANCE LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 102 FRANCE LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)
TABLE 103 FRANCE LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 104 ITALY LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 105 ITALY IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 106 ITALY CALCINEURIN INHIBITORS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 107 ITALY ANTIMETABOLITE IMMUNOSUPPRESANTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 108 ITALY M-TOR INHIBITOR IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 109 ITALY STEROIDS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 110 ITALY MONOCLONAL ANTIBODY IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 111 ITALY IMMUNOSUPRRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 112 ITALY IMMUNOSUPPRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 113 ITALY ORGAN PRESERVATION PRODUCTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 114 ITALY LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 115 ITALY LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 116 ITALY LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 117 ITALY LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)
TABLE 118 ITALY LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 119 U.K. LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 120 U.K. IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 121 U.K. CALCINEURIN INHIBITORS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 122 U.K. ANTIMETABOLITE IMMUNOSUPPRESANTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 123 U.K. M-TOR INHIBITOR IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 124 U.K. STEROIDS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 125 U.K. MONOCLONAL ANTIBODY IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 126 U.K. IMMUNOSUPRRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 127 U.K. IMMUNOSUPPRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 128 U.K. ORGAN PRESERVATION PRODUCTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 129 U.K. LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 130 U.K. LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 131 U.K. LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 132 U.K. LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)
TABLE 133 U.K. LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 134 BELGIUM LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 135 BELGIUM IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 136 BELGIUM CALCINEURIN INHIBITORS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 137 BELGIUM ANTIMETABOLITE IMMUNOSUPPRESANTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 138 BELGIUM M-TOR INHIBITOR IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 139 BELGIUM STEROIDS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 140 BELGIUM MONOCLONAL ANTIBODY IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 141 BELGIUM IMMUNOSUPRRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 142 BELGIUM IMMUNOSUPPRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 143 BELGIUM ORGAN PRESERVATION PRODUCTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 144 BELGIUM LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 145 BELGIUM LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 146 BELGIUM LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 147 BELGIUM LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)
TABLE 148 BELGIUM LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 149 NETHERLANDS LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 150 NETHERLANDS IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 151 NETHERLANDS CALCINEURIN INHIBITORS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 152 NETHERLANDS ANTIMETABOLITE IMMUNOSUPPRESANTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 153 NETHERLANDS M-TOR INHIBITOR IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 154 NETHERLANDS STEROIDS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 155 NETHERLANDS MONOCLONAL ANTIBODY IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 156 NETHERLANDS IMMUNOSUPRRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 157 NETHERLANDS IMMUNOSUPPRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 158 NETHERLANDS ORGAN PRESERVATION PRODUCTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 159 NETHERLANDS LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 160 NETHERLANDS LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 161 NETHERLANDS LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 162 NETHERLANDS LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)
TABLE 163 NETHERLANDS LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 164 SWITZERLAND LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 165 SWITZERLAND IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 166 SWITZERLAND CALCINEURIN INHIBITORS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 167 SWITZERLAND ANTIMETABOLITE IMMUNOSUPPRESANTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 168 SWITZERLAND M-TOR INHIBITOR IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 169 SWITZERLAND STEROIDS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 170 SWITZERLAND MONOCLONAL ANTIBODY IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 171 SWITZERLAND IMMUNOSUPRRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 172 SWITZERLAND IMMUNOSUPPRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 173 SWITZERLAND ORGAN PRESERVATION PRODUCTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 174 SWITZERLAND LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 175 SWITZERLAND LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 176 SWITZERLAND LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 177 SWITZERLAND LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)
TABLE 178 SWITZERLAND LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 179 RUSSIA LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 180 RUSSIA IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 181 RUSSIA CALCINEURIN INHIBITORS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 182 RUSSIA ANTIMETABOLITE IMMUNOSUPPRESANTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 183 RUSSIA M-TOR INHIBITOR IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 184 RUSSIA STEROIDS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 185 RUSSIA MONOCLONAL ANTIBODY IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 186 RUSSIA IMMUNOSUPRRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 187 RUSSIA IMMUNOSUPPRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 188 RUSSIA ORGAN PRESERVATION PRODUCTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 189 RUSSIA LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 190 RUSSIA LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 191 RUSSIA LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 192 RUSSIA LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)
TABLE 193 RUSSIA LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 194 TURKEY LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 195 TURKEY IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 196 TURKEY CALCINEURIN INHIBITORS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 197 TURKEY ANTIMETABOLITE IMMUNOSUPPRESANTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 198 TURKEY M-TOR INHIBITOR IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 199 TURKEY STEROIDS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 200 TURKEY MONOCLONAL ANTIBODY IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 201 TURKEY IMMUNOSUPRRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 202 TURKEY IMMUNOSUPPRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 203 TURKEY ORGAN PRESERVATION PRODUCTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 204 TURKEY LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 205 TURKEY LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 206 TURKEY LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 207 TURKEY LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)
TABLE 208 TURKEY LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 209 REST OF EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
Lista de Figura
FIGURE 1 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: SEGMENTATION
FIGURE 2 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: DROC ANALYSIS
FIGURE 4 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: MARKET END USERS COVERAGE GRID
FIGURE 8 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: SEGMENTATION
FIGURE 11 TECHNOLOGICAL ADVANCEMENTS IN HEALTHCARE AND SURGICAL SEGMENTS ASSOCIATED WITH ORGAN TRANSPLANTATION IS EXPECTED TO DRIVE THE EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 IMMUNOSUPPRESSANTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET IN 2022 & 2029
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET
FIGURE 14 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: BY PRODUCT, 2021
FIGURE 15 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: BY PRODUCT, 2020-2029 (USD MILLION)
FIGURE 16 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: BY PRODUCT, CAGR (2022-2029)
FIGURE 17 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 18 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: BY TECHNIQUE, 2021
FIGURE 19 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: BY TECHNIQUE, 2020-2029 (USD MILLION)
FIGURE 20 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: BY TECHNIQUE, CAGR (2022-2029)
FIGURE 21 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: BY TECHNIQUE, LIFELINE CURVE
FIGURE 22 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: BY PATIENT DEMOGRAPHICS, 2021
FIGURE 23 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)
FIGURE 24 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: BY PATIENT DEMOGRAPHICS, CAGR (2022-2029)
FIGURE 25 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: BY PATIENT DEMOGRAPHICS, LIFELINE CURVE
FIGURE 26 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: BY TYPE, 2021
FIGURE 27 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: BY TYPE, 2022-2029 (USD MILLION)
FIGURE 28 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 29 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 30 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET : BY INDICATION, 2021
FIGURE 31 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET : BY INDICATION, 2020-2029 (USD MILLION)
FIGURE 32 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET : BY INDICATION, CAGR (2022-2029)
FIGURE 33 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET : BY INDICATION, LIFELINE CURVE
FIGURE 34 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET : BY END USER, 2021
FIGURE 35 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET : BY END USER, 2020-2029 (USD MILLION)
FIGURE 36 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET : BY END USER, CAGR (2022-2029)
FIGURE 37 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET : BY END USER, LIFELINE CURVE
FIGURE 38 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: SNAPSHOT (2021)
FIGURE 39 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: BY COUNTRY (2021)
FIGURE 40 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 41 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: BY COUNTRY (2021 & 2029)
FIGURE 42 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: BY PRODUCT (2022-2029)
FIGURE 43 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: COMPANY SHARE 2021 (%)
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.
A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.
Personalização disponível
A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.
